Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Holdings Decreased by Emerald Advisers Inc. PA

Emerald Advisers Inc. PA decreased its position in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 8.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 552,942 shares of the specialty pharmaceutical company’s stock after selling 52,978 shares during the quarter. Emerald Advisers Inc. PA owned about 1.08% of Supernus Pharmaceuticals worth $22,035,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Thomson Horstmann & Bryant Inc. increased its holdings in shares of Supernus Pharmaceuticals by 8.8% during the fourth quarter. Thomson Horstmann & Bryant Inc. now owns 28,556 shares of the specialty pharmaceutical company’s stock valued at $1,137,000 after acquiring an additional 2,305 shares in the last quarter. Neuberger Berman Group LLC bought a new stake in Supernus Pharmaceuticals during the third quarter worth $660,000. Braun Stacey Associates Inc. bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth $440,000. Royal Bank of Canada grew its holdings in Supernus Pharmaceuticals by 790.8% during the second quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock worth $11,699,000 after buying an additional 240,978 shares in the last quarter. Finally, First Trust Advisors LP bought a new stake in Supernus Pharmaceuticals during the third quarter worth $2,255,000. Hedge funds and other institutional investors own 98.20% of the company’s stock.

In related news, VP Victor Vaughn sold 5,750 shares of the stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $45.03, for a total transaction of $258,922.50. Following the sale, the vice president now owns 15,094 shares of the company’s stock, valued at approximately $679,682.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the firm’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $48.04, for a total value of $960,800.00. Following the completion of the sale, the vice president now directly owns 32,500 shares in the company, valued at approximately $1,561,300. The disclosure for this sale can be found here. Insiders have sold a total of 165,750 shares of company stock worth $7,133,973 in the last three months. 6.70% of the stock is currently owned by insiders.

Several brokerages recently issued reports on SUPN. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a report on Wednesday, January 10th. BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 11th. Berenberg Bank assumed coverage on Supernus Pharmaceuticals in a research note on Thursday, February 1st. They issued a “buy” rating and a $66.00 price objective for the company. B. Riley restated a “buy” rating and issued a $50.00 price objective (down previously from $53.00) on shares of Supernus Pharmaceuticals in a research note on Monday, November 6th. Finally, SunTrust Banks restated a “buy” rating and issued a $61.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, November 3rd. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Supernus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $51.36.

Shares of Supernus Pharmaceuticals Inc (NASDAQ SUPN) traded down $0.55 during midday trading on Wednesday, hitting $38.10. The stock had a trading volume of 306,400 shares, compared to its average volume of 748,328. Supernus Pharmaceuticals Inc has a 1 year low of $24.65 and a 1 year high of $50.04. The stock has a market cap of $2,020.00, a PE ratio of 34.64 and a beta of 1.08.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The firm had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. The business’s quarterly revenue was up 41.5% compared to the same quarter last year. equities analysts predict that Supernus Pharmaceuticals Inc will post 1.07 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Holdings Decreased by Emerald Advisers Inc. PA” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/14/emerald-advisers-inc-pa-sells-52978-shares-of-supernus-pharmaceuticals-inc-supn.html.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply